More than 40 years after beta blockers were first used clinically,
scientists can finally get a close-up look at the drugs’ molecular
target-the b2-adrenergic receptor. The
work is particularly exciting because it offers the first glimpse
into an important, but scientifically elusive family of human proteins
called G protein-coupled receptors (GPCRs).

More than 40 years after beta blockers were first used clinically,
scientists can finally get a close-up look at the drugs’ molecular
target-the b2-adrenergic receptor. The
work is particularly exciting because it offers the first glimpse
into an important, but scientifically elusive family of human proteins
called G protein-coupled receptors (GPCRs).